Lakewood-Amedex Secures Australian Patent for Bisphosphocin Compounds in UTIs and Pulmonary Infections
LABT•Lakewood-Amedex Biotherapeutics has received an Australian composition-of-matter patent for its Bisphosphocin® class targeting complicated urinary tract and pulmonary infections. This adds to its global portfolio of 72 granted and 29 pending patents across jurisdictions including the US, Europe, China, India and Japan.
1. Australian Patent for Bisphosphocin Compounds
On March 5, 2026, IP Australia issued a composition-of-matter patent covering Lakewood-Amedex’s novel Bisphosphocin® class compounds being developed for complicated urinary tract and pulmonary infections.
2. Expanded Global IP Portfolio
This award increases the company’s intellectual property portfolio to 72 granted patents and 29 pending applications across markets including the United States, European Union, China, India, Japan, Mexico, and the Republic of Korea.
3. Commercial and Clinical Implications
The strengthened patent position enhances Lakewood-Amedex’s ability to protect its antimicrobial platform against resistance threats, supports potential licensing or partnership deals, and reinforces its development strategy addressing antibiotic-resistant pathogens such as MRSA and VRE.
